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Cancer stem cell population is a subset of cells capable of dictating invasion, metastasis, heterogeneity, and therapeutic resistance
in tumours. Eradication of this rare population is a new insight in cancer treatment. However, prospective identiﬁcation, charac-
terization, and isolation of these CSCs have been a major challenge. Many studies were performed on surface markers for potential
identiﬁcation and isolation of CSCs. Lack of universal expression of surface markers limits their usage and no best combination of
markershasyetbeenconﬁrmedtoidentifyCSCscapableofinitiatingandmetastasizingtumours.CD44,ahyaluronicacidreceptor,
is one of the most commonly studied surface markers, which is expressed by almost every tumour cell. CD24, a heat stable antigen,
is another surface marker expressed in many tumour types. However, their expression and prognostic value in isolating CSCs are
still an enduring ambiguity. In this critical review, we assess the role of CD44 and CD24 in tumour initiation, development, and
metastasis.WemainlyfocusonanalysingthesigniﬁcanceofCD44andCD24asCSCsurfacemarkersincombinationorwithother
putative markers in diﬀerent types of cancer.
1.Introduction
Cancer stem cells (CSCs) can be deﬁned as a population of
cellspresentintumours,whichcanundergoself-renewaland
diﬀerentiation. Similar to normal stem cells, CSCs can also
give rise to all cancer cells in a tumour and hence termed
cancer stem cells. Overwhelming evidence supports the vital
role of this subset of cells in initiation and maintenance
of a tumour in addition to their capability to dictate inva-
sion, metastasis, heterogeneity, and therapeutic resistance in
tumours. Identiﬁcation and isolation of these CSCs using
putative surface markers have been a priority of research in
cancer. However, deﬁnition of speciﬁc CSC surface markers
in all cancer types requires further investigations. It is clear
that heterogeneity amongst tumours and within tumour
subtypes renders it diﬃcult to discover unique markers. Sur-
face markers exhibit variable expression levels at diﬀerent
stages of tumour while their key regulatory functions remain
unclear. However, with advancement of knowledge in this
concept, the well-accepted cancer stem cell surface markers
are CD44, CD24, CD133, CD166, EpCAM, and so forth, in
diﬀerent tumours including breast, lung, pancreas, prostate,
colorectal, renal, and ovarian, while the prognostic value of
these markers is still under investigation. Although cells in
tumours expressing these markers possess stem cell charac-
teristics, the question is whether they have true potentials to
initiate and metastasize tumours. Therefore, alternate spe-
culation is CSCs may not be termed as tumour-initiating
cells. Thus, it demands urgent need of speciﬁc markers that
can distinguish and target these CSCs. No best combination
o fm a r k e r sh a sy e tb e e nc o n ﬁ r m e dt oi d e n t i f yC S C st h a t
are capable of initiating and metastasizing tumours. Several
stem cell surface markers and biomarkers are being exploited
in various cancers to determine a principal pattern of CSC
markers. Proper screening and proﬁling of each marker with
r e s pe ctt oe a c ht u m o u rtypea n dt u m o u rs u b typei sv e ryvi t a l
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CD44 and CD24 have been used extensively in combi-
nation or with other putative markers to isolate CSCs from
solid tumours [1, 2]. However, the lack of their universal ex-
pression limits their usage to few designated cancer types.
Owing to current contradictions, we herein review recent
literature and discuss the importance of CD44 and CD24, as
potential surface markers in identiﬁcation and isolation of
CSC, in diﬀerent cancers. We also discuss CSCs diﬀerential
proportionalitiesinvariouscancercelllinesandmechanisms
involved in interconversion of CD44 and CD24 phenotypes.
2. Cancer Stem Cell Concept: Primary View
Cancerstemcell(CSC)conceptisanexcitingareaofresearch
in cancer that generates a pronounced avenue to unravel and
exploitnovelstrategiesfortreatingcancer.Overadecadeago,
studies on acute myeloid leukaemia had pioneered the CSC
concept from CD34+CD38− phenotype [3, 4]. With subse-
quent studies [5, 6], the existence of CSC in solid tumours
is now acceptable with distinct phenotypic and functional
abilities to generate tumours in xenograft models [7, 8].
These are also termed as tumour-initiating cells, which are
not unanimously accepted [9]. CSCs exhibit eﬃcacy in
tumourigenesis, metastasis, and therapeutic resistance [10].
Eradication of this rare population is a new insight in can-
cer treatment [11, 12], but prospective identiﬁcation, char-
acterization, and isolation of these CSCs have been a major
challenge. Heterogeneity amongst tumours and tumour cells
[13], complex mechanisms and lack of speciﬁc markers to
target them are the frontline hurdles in CSC theory [14–16].
Moreover, the origin of CSCs is debatable and uncer-
tainty still continues. The major question is how these cells
could maintain self-renewability with speciﬁc diﬀerentiation
pathways [12]. Some postulations were made that normal
stem cells and their progenitors could manifest CSCs activity
as a consequence of accumulated mutations [9, 17]. But this
may not be the sole source and cannot be applied to all CSCs
[18]. If the signalling and molecular pathways were consid-
ered from normal stem cells, CSCs seem to have a possible
connection with Wnt, Hedgehog (Hh), and Notch signalling
pathways. Aberrant mutations due to several environmental
factors and carcinogens such as cigarette smoke, radiations,
and reactive oxygen species (ROS) [19]m a yc a u s er e p r o -
gramming of epigenetic machinery and extensive changes in
the DNA [20] that can deregulate the genes involved in these
signalling pathways [21]. Consequently, the hyperactivation
of these pathways is believed to cause tumourigenesis [22].
Moreover, the heterogeneity amongst tumour cells also in-
dicate the possibility of diﬀerent mechanisms in these signal-
ling pathways where several arguments still exist [12]. Like-
wiseinnormalstemcells,itwasreportedthatCSCsalsocon-
tain lower levels of ROS associated with higher expression
of ROS scavengers. Targeting ROS scavengers may induce
the alterations in CSC signalling cascades [23]. Therefore,
thecorrelationandcross-talkbetweentranscriptionalfactors
and protein molecules involved amongst these embryonic
signalling pathways in tumour microenvironment may need
extensive understanding [24, 25]. More detailed studies
could give a clear picture of molecular pathways and reveal
the origin of CSCs to help developing strategies for novel
therapeutics in cancer.
3.AnUnsettledRace amongst CSCMarkers
There are some putative stem cell markers that are in major
use for identiﬁcation and isolation of CSCs from diﬀerent
solid tumours [13, 15, 26]. CD44 is considered a potential
CSC marker in majority of cancers [15]. CD24 is another
important marker whose prognostic value and signiﬁcance
remains controversy [7, 27]. CD24 has been investigated in
combination with CD44 and other markers in various can-
cers. Following the identiﬁcation of CSCs in breast cancer
[28], these two markers gained a considerable interest to
study their signiﬁcance as CSC surface markers in other can-
cers.Thoughthecurrentlyavailablemarkerslookpromising,
theyarenotspeciﬁctoallcancersandwithincancersubtypes
[7, 29]. These markers may work eﬃciently in combination
with diﬀerent markers but their suitable counterparts are
yet to be conﬁrmed. Nonetheless, emerging evidences are
continuing to explore their functional properties and mech-
anisms in tumour cells. The exploitations of these markers
are still providing many interesting postulations yet to be
concluded.
4. Molecular Functionalitiesof CD44 in
Normal andCancerCells
CD44 is a multifunctional class I transmembrane glycopro-
tein [30] generally acts as a speciﬁc receptor for hyaluronic
acid, promoting migration in normal cells and highly ex-
pressed in almost every cancer cell in its standard or variant
form [31]. It is mainly associated with proteins that monitor
the extracellular changes and critical in regulating cell ad-
hesion, proliferation, growth, survival, motility, migration,
angiogenesis, and diﬀerentiation [15, 30]. Also, CD44 pre-
sents cytokines and chemokines to their complimentary
receptors on the cellular membrane [30]. CD44 interacts
with osteopontin and regulates its cellular functions leading
to tumour progression [32]. It even interacts with collagen,
laminin, and ﬁbronectin where their physiological function
isunclear[31].CD44functionsinvolveligandbindingrecep-
tor, coreceptor and organizer in cortical actin skeleton [30].
CD44 is expressed on cancer cell surface and assist haemato-
genous spread while interacting with P- or L-selectins [33].
It is also involved in numerous complex signalling cascades
enhancingtumourinitiationsbyinteractingwithneighbour-
ing receptors like tyrosine kinase [34].
Though the above-mentioned functions are physiologi-
cal activities in normal and stem cells, they are in turn ex-
hibited in cancer cells as well. CD44 gene often undergoes
alternative splicing to encode diﬀerent proteins in diﬀerent
cancer subtypes [32], displaying its multifaceted expression.
Hence, CD44 is extensively used as a surface marker for iso-
lating CSCs from breast, prostate, pancreas, ovarian, and
colorectal cancers [15, 35]. In combination with other sur-
face markers, CD44 can also discriminate between a varietyClinical and Developmental Immunology 3
of cancer subsets [36]. As few as 100 cells, CD44+cells pro-
moted tumourigenesis in breast, and colorectal cancer dis-
playing stem cell properties such as self-renewal and dif-
ferentiation.
However, there are contradictions in validating CD44 ex-
pression level and correlation with disease prognosis. For
several years, the usefulness of CD44 as CSC marker has
been uncertain [1]. In many cancers, CD44 plays a major
role in initiation [26], metastasis [29, 37, 38], and promoting
tumourigenesis [39]; while other studies opposed this rela-
tionship in other human cancers like breast [40]a n dp r o s -
tate [41] cancers, where its high expression also showed no
carcinogenesis [42]. CD44 is expressed in almost all normal
and cancer cells leading to discrepancy and reﬂecting the
ambiguity regarding functional aspects of CD44 in CSC
maintenanceand mechanisms involved in cross-talkwithex-
pression of stemness genes [15].
5. Molecular Functionalitiesof CD24 in
NormalandCancerCells
CD24 is a small cell surface protein molecule anchored by
glycosyl-phosphotidyl-inositol in a wide variety of cancer
cells. It is heavily glycosylated and functions in cell-cell and
cell-matrix interactions [2, 43, 44]. CD24 was discovered in
mice as a heat-stable antigen and was used as a marker to
diﬀerentiate hematopoietic cells and neuronal cells [45, 46].
Variable glycosylation on CD24 attributes to distinct func-
tions in diﬀerent cells in which some are still unclear. Due to
itsdistinctglycosylation,itactsasaversatileligandinvarious
cells including cancer cells with diverse physiological func-
tions, making its mechanisms more complex to understand
[46].
CD24 is highly expressed in ovarian, breast, prostate,
bladder, renal, nonsmall cell carcinomas, and other human
cancers [43, 47]. It is involved in cell adhesion and metastasis
[2]. This indicates that CD24 could be a signiﬁcant marker
in tumour prognosis and diagnosis. Functionally, it is iden-
tiﬁed as an alternate ligand for P-selectin, an adhesion recep-
tor on platelets and endothelial cells [48], through which
their interaction facilitates the passage of tumour cells in
blood stream during metastasis. It increases proliferation
and adhesion of tumour cells to ﬁbronectin, collagen, and
lamin [47]. The metastatic associations of CD24 increase its
importanceasaprognosticfactorandanewCSCmarker[2].
Recent investigations found that CD24 is coexisting with
CD44, CD29, and CD31 in various cancers and gained new
interest as a CSC marker. High expression of CD24 is in-
volved in tumour progression [2] and metastasis [29], while
the intracellular studies in pancreatic cancer [49] showed
CD24 expression both on membrane surface and intracel-
lular environment but inhibited the cell invasion and metas-
tasis. This indicates the distinct expression and function of
CD24 in diﬀerent cancers. Also CD24 appears to possess
less expression in progenitor cells when compared to diﬀer-
entiated cells. Hence, studies are required on its underlying
mechanisms in both diﬀerentiated and undiﬀerentiated cells
[46].
6.AreCD44 andCD24 Reliable CSCMarkers?
Many studies refer to CD44 as a commonly expressed surface
marker in diﬀerent cancer types. The majority of cancer cell
lines express high levels of CD44. Diﬀerently and in spite
of its expression in many diﬀerent cancer subtypes, the
ambiguityonCD24classiﬁcationanddistributionisstillper-
sisting. The conclusions from several studies regarding their
expression, role in tumour initiation, and metastasis, and
membrane distribution appear to be diﬀerent [26, 50–53].
However, including CD44 and CD24, no marker can be used
universally to identify CSCs in various cancers. It is cer-
tainly acceptable that these markers are not expressed in all
cancers. We found that the levels of CD44 and CD24 expres-
sion show great variation (Figure 1) between cell lines even
in cells of the same cancer subtype [53]. They are engaged
with distinct functionalities at diﬀerent time periods during
tumour progression and metastasis [18]. It strongly infers
heterogeneity between and amongst cancer subtypes, which
is not fully elucidated [50] and raises a question of credibility
regarding their value as CSC surface markers. Despite the
extensive study and emerging evidence, signiﬁcance of CSC
markers,theirspeciﬁcity,correlation,andcoexistenceremain
elusive. Also, enormous data from literature is leaving am-
biguity even for the same type of cancer subtypes and CSC
markers. Collectively, CSC concept seems to be left more
complicated with complex implications yet to be resolved.
7. Proportions of CSCs and Expression Level of
CD44andCD24Markers
I n i t i a l l yC S C sw e r ec o n s i d e r e dt ob eav e r yr a r es u b s e to f
cells in tumours characterized with stem cell properties and
tumour initiating capability [18]. According to early studies,
it was 0.1%–1% in leukaemia and 2% in breast cancer [4,
5, 28], which was later supported by many scientists. Recent
studies in colorectal cancer cell lines showed 0.5%–1% of
CD44+/CD24+ cells gave rise to the highest proportion of
crypt-forming megacolonies and diﬀerentiated to all combi-
nations of CD44±/CD24± [8]. More recently, Ricardo et al.
[7] demonstrated the frequency of CD44+/CD24−/low as
≥10% in basal-like breast tumours. In contrast, a recent
mathematical model proposed that CSCs could be any
possible proportion of the tumour and its tumourigenesis is
directly proportional to the number of CSCs [54].
However, studies on cancer cell lines showed substantial
variation in CD44 and CD24 expression. Study on NC160
tumour cell lines panel by Stuelten et al. [53] found that
CD44 and CD24 expression is highly varied even amongst
same tumour type cell lines. In support of these results, ano-
ther study in ovarian cancer observed great variation in
CD44 and CD24 expression in almost all patients ranging
from2.2%–88.2% and3.2%–86.7%, respectively,[55].How-
ever, there is a discrepancy with the results amongst other
scientists. Subsequent studies by Leung et al. [26] and others
claimed that their results diﬀer from Stuelten and colleagues.
Also, in our preliminary study on selected cancer cell lines,
we observed a range of variation in CD44 and CD244 Clinical and Developmental Immunology
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Figure 1: FACS analysis for double staining of CD44 and CD24 in selected human cancer cell lines. These cell lines are breast (MDA-MB-
468), renal (CAKI2), colon (HCT116), lung (COR L23), and ovarian cancer (OVCAR3, SKOV3, CAOV3 and A2780). Each cancer cell line
shows diﬀerential expression for both CD44 and CD24. It is highly variable even amongst cell lines of same cancer types indicating the
heterogeneity between tumours.
expression even amongst same cancer types (Figure 1). We
also observed that data diﬀers in these two studies. The per-
sisting inconsistency amongst emerging data consequently
may mislead the conclusions. One of the main reasons for
this diﬀerence from study to study could be the variation
in selected samples. Data from individual cell in culture
may vary from primary tissue or colony-forming cells or
transition cells due to distinct morphological and microen-
vironmental properties [18]. For instance, a recent study on
cells from primary ovarian carcinoma in diﬀerent patients
expressedCSCsurfacemarkersatdiﬀerentlevels[55].There-
fore, until now, there are no precise proportions of CSCs or
individual markers capable of initiating and metastasizing
tumours.
8. Correlationbetween CD44, CD24 Expression
andMetastasis
With advancement of studies in CSCs, the correlation bet-
ween marker expression, tumour initiation, invasion, and
metastatic properties has been questioned [8, 56]. Further-
more, coexpression of surface markers in CSCs is sometimes
debatable in several cancer types. Every marker shows in-
dependent expression level but seems to have coordination
with each other in developing tumours at diﬀerent stages. A
recent study demonstrated no correlation between marker
expression and tumourigenic potentiality in CSCs of the
same cancer type obtained from diﬀerent patients [55].
Abraham et al. [57] demonstrated ≤10% prevalence of
CD44+/CD24− in 78% and >10% of these cells in 22% of
breast cancer samples and extended to suggest that there is
nocorrelationbetweentheprevalenceofCD44+/CD24− cells
and clinical outcome but indicated the chance of metastasis.
In contrast, Sheridan et al. [56] demonstrated that there is
nocorrelationbetweentheprevalenceofCD44+/CD24− cells
with distant metastasis. This phenotype is associated with
invasive properties but lacks the ability to proliferate. Sup-
porting these two ﬁndings, Fillmore and Kuperwasser [58]
also showed that there is no correlation between the per-
centage of CD44+/CD24− cells and tumourigenicity. Later
on Choi et al. demonstrated that CD133, CD24, and CD44
expression is related to invasiveness and diﬀerentiation but
did not show a close relationship with the survival outcome
of colorectal adenocarcinoma [59]. Stuelten et al. [53] also
showed no correlation between the marker expression and
their clonogenic potentiality in cell lines. But very recently,
and for the ﬁrst time, a study in colorectal cancer re-
vealed coexistence of CD133+ CD44+ stem-like cells with
CD133+CD44high subset that exhibited more invasive in vitro
and metastasis to liver in vivo [60]. However, direct inves-
tigations on metastatic ability of CSCs in vivo are very few
and more validations are required. Signiﬁcantly, it was found
that CSCs express invasive genes in vivo but are incapable of
metastasis [61].Clinical and Developmental Immunology 5
9. Strategies Implemented on CD44 and
CD24 toEvaluateTheirSigniﬁcanceas
CSCSurfaceMarkers
It is highly convincing that tumour recurrence can be pre-
vented if CSCs are speciﬁcally targeted. Development of
drugs to target and eradicate CSCs represents a major chal-
lenge due to the fact that they are resistant to conventional
therapies. The slow replication rate of cancer stem cells com-
pared to adult cancer cells and overexpression of ABC trans-
porter proteins that are capable of eliminating the molecules
used in cancer therapies could be possible reasons for in-
herent resistance in CSCs [59, 62]. Regulation of CD44 or
CD24 expression in various cancers seems to be eﬀective in
controlling tumour initiation and inhibition of CSC popula-
tion. Jin et al. [63] demonstrated reduction of leukemic stem
cells in acute myeloid leukaemia by targeting CD44 function.
Therefore, CD44 could be a potential therapeutic target in
solid tumours that are expressing this molecule. However,
the inﬂuence of alteration in CD44 function on normal stem
cellshastobeconsideredduringexperimentsonacancerpa-
tient [29].
Genetic manipulations of certain surface marker expres-
sion in CSCs and examining the eﬀect on cancer progression
have been under investigation. MicroRNA (miRNA) has
been used to downregulate speciﬁc gene functions in CSCs
and repress their expression in order to understand their
key functional activities. They are also being used to inhibit
proliferation and induce apoptosis, senescence when trans-
fected into cancer cells [64]. By using these approaches, in-
ducing the diﬀerentiation of CSCs may transform them to
mature cancer cells which can be more vulnerable to
conventional therapies [65]. This miRNA could be advan-
tageous in treating malignant tumours by repressing spe-
ciﬁc genes of signalling pathways involved in CSCs [11].
Previous studies [66, 67] demonstrated these strategies. Yu
et al. [68] work with let-7 miRNA in breast-cancer-induced
CD44+/CD24−/low cell population to diﬀerentiate and con-
sequently inhibited formation of tumours. Using mullerian-
inhibiting hormone, Wei et al. [69] demonstrated inhibi-
tion of stem/progenitor cell population in tumours. More
recently, Liu et al. [64] showedthatmiR-34a inhibits prostate
cancer stem cells and metastasis by directly repressing CD44
expression. However, widespread explorations of miR-34a
functionalitiesarenecessaryforcompleteunderstandingand
could be considered for further therapeutic implications
[70]. Recent studies on CD24 depletion using siRNA and
NDRG2 regulation in hepatocellular carcinoma [47, 71]a n d
shRNA methods in bladder cancer [72] demonstrated the
reduction of tumourigenesis and CD24 could be used as a
prognostic marker. However, absence of CD24 expression in
breastandprostatecancerrestrictsitsuseasapotentialtarget
for controlling invasion and metastasis [73]. This suggests
that CD24 expression seems to be strictly tissue speciﬁc and
more elucidations necessary to develop more obvious thera-
peutic strategies. However, the miRNA application has to be
viewed as a strategy to analyse the expression and regulatory
function of a particular gene in diﬀerent cell types. At this
context, it may be helpful in understanding the role of a sur-
face marker in driving tumour initiation and metastasis of
diﬀerent tumour types. Knock-down of CD44 or CD24 may
enhance CSC diﬀerentiation to mature cells and reduce tu-
mour progression [74]. Targeting key regulatory genes in
CSCsmaycontroltheircriticalsignallingpathways,butithas
to be speciﬁc to targeting genes expressed in only CSCs but
not normal stem cells [29].
10.CD44+/CD24−/low asBreast CSCMarker
AfterpioneeringstudiesofAl-Hajjetal.[28]inhumanbreast
cancer, CD44+/CD24−/low cells were recognized as prospec-
tive cancer stem cells for basal/mesenchymal cell lines MCF
7 and MDA-MB-231. This was subsequently supported by
Sheridan et al. [56] but suggesting this phenotype alone may
not be appropriate to envisage metastasis though these cells
are rich in invasive genes. Later on, large body of evidence
demonstrated that this phenotype is not expressed in all
breast cancers emphasizing the need for identiﬁcation of
other breast CSC markers [7, 50, 51].
MDA-MB-468 cell line exhibits high expression of
CD44+/CD24+ cells with basal/epithelial phenotype [7]. We
found similar results in our ﬂow cytometric studies on this
cell line (Figure 1). It is highly accepted that CD44+/ CD24−
exhibit undiﬀerentiated basal/mesenchymal cell properties
and CD44+/CD24+ exhibit highly diﬀerentiated basal/epi-
thelial cell properties [7]. But how epithelial cell lines like
MDA-MB-468 with high CD24 expression could induce
tumours remains unclear. Though MDA-MB-468 is rich in
CD44+/CD24+ cells that are not invasive, it is believed that
few CD44+/CD24− cells in this cell line are progressed to
CD44+/CD24+phenotype after metastasis which seem to
have an interconversion of CD24+ to CD24− [56]. Recent
studies are evident for migration, colony formation, and in-
vasion in MDA-MB-468 by CD44+ cells that give support
to the CD24 interconversion and regulatory concept [75].
Shipitsin and Polyak [76] hypothesized relationship between
CD44+ and CD24+ genotypes and their origin. In another
study, Honeth et al. [50] found predominant expression of
CD24 in cytoplasm along with CD44 high expression on sur-
face membrane, but disturbances in protein distribution or
its degradation may regulate enrichment of CD24 on mem-
brane. It seems that few alterations may take place in reg-
ulating the level of CD24 expression on membrane surface
during tumour initiation and metastasis. Subsequently,
Meyer et al. [77] supported the possibility of interconversion
between the phenotypes and suggested that epithelial like
CD44+/CD24+can readily give rise to CD44+/CD24− cells
during tumour initiation. Also, these studies supported the
possibility for CD24+ origin from CD44+ cells indicating
they are genetically identical [29]. Based on the same con-
cept, recently, Shi et al. [78] also demonstrated in human
epithelial ovarian cancer, that CD44+/CD24− cells showed
CSC-like properties and diﬀerentiated to CD44+/CD24+.A
r e c e n ts t u d yb yR i c a r d oe ta l .[ 7] has indicated more addi-
tional questions that to be elucidated. Until recently ALDH1
wasconsideredasoneofthepotentialmarkersforidentifying6 Clinical and Developmental Immunology
breast cancer stem cells along with CD44+/CD24−/low.I t
seems CD44+/CD24−/low phenotype and high ALDH1 ex-
pression overlap at signiﬁcantly low proportion of 1% [79].
Ricardo et al. concluded that little overlap between these two
markers limits their prognostic value even amongst basal-
like subtypes in breast cancer indicating the distinct diﬀeren-
tiation amongst same cancer subtypes.
Regardless of the positivity or negativity of CD44 and
CD24, the cells expressing these markers in breast cancer
were highly acknowledged with invasive properties but lack-
ing metastatic genes [56]. Although many studies proved the
vital role of CD44 in metastasis [34, 80], contrastingly, Lopez
et al. [40] demonstrated that CD44 can inhibit metastasis
in the breast cancer. On the other hand, activity of CD24
was also having the similar attention with contradictory ex-
planations. Baumann et al. [81] showed CD24 promotes in-
vasion, while Schabath et al. [52] demonstrated expression
of CD24 inhibiting the invasion and metastasis. Conversely,
the prognostic value of these markers in breast cancer is still
a controversy, which needs more research to disclose these
complications [7, 27]. Therefore, these markers cannot be
referred as supreme markers for identifying breast cancer
stem cells [9].
11. Ambiguityover CD44and CD24Expression
inOvarianCancer
The variations in CD44 and CD24 proportions from cell line
to cell line show the phenotypic heterogeneity in diﬀerent
cancer types (Figure 1). Our data represent similar results
with past evidences and indeed contrasting with some other
studies too. Nevertheless, there is a great demand for more
intensive studies in addition to current investigations of
CSCs in various cancer types. This notion of identifying
potential CSCs has also directed its extensions to ovarian,
prostate, pancreas, colorectal, renal, and lung cancers. CD44
and CD24 have been studied extensively to determine their
signiﬁcance as CSC markers. Apart from CD44 expression,
CD24+ cells are also reported to act as cancer stem cells in
ovarian and colorectal cancers [8]. Therefore, the signiﬁ-
cance of CD24 expression cannot be overruled.
Ovarian cancer cell lines show high expression of CD24
astheyhaveepithelialphenotype[82].Withcriticalreviewof
literature, it appears that the importance of CD44 and CD24
expression in ovarian cancer is more debatable. It is realized
that there are no potential markers to detect ovarian cancer
at an early stage and they are not studied completely [35, 83].
From initial studies [84] in human ovarian cancer, both side
population (SP) and non-SP in one cell line (MOVCAR8)
showed high expression of CD44 whereas other human
ovarian cancer cell lines do not express CD44. In the same
study, the authors indicated that CD24 showed variable
expression in these cell lines. Following these studies, Zhang
et al. [85] demonstrated that CD44+CD117+ cells have the
potential to initiate epithelial ovarian cancer, which was later
s u p p o r t e db yo t h e rs t u d i e sa sw e l l[ 55, 86, 87]. Additionally,
Slomiany et al. [1] reported that CD44+CD117+ phenotype
has a prognostic value in combination with CD133. But in
c o n t r a s t ,ar e c e n ts t u d y[ 88] reported that CD117 is not en-
riched in most of the ovarian cancer cell lines. Although
CD44 appears to be a promising marker in several ovarian
cancer cell lines, it cannot be used solely, and other potential
markers should be combined in order to characterise and
isolate CSCs.
According to published data on diﬀerent ovarian cancer
cell lines, there appear to be substantial variations in propor-
tions of CD44 and CD24. For instance, CD44 expression is
high in SKOV3 but no expression found in OVCAR3 [36, 89,
90], which is similar to our results (Figure 1). Previous stud-
ies also demonstrated the CD44 expression in SKOV3 and
CAOV3 [91]. In contrast, there are also recent studies argu-
ing high expression of CD44 in OVCAR3 [92, 93]. It is also
thesameparadigmwithA2780whereRainaldietal.[94]and
Santini et al. [95] stated the absence of CD44 in A2780, while
another recent study [96] demonstrated high expression of
CD44 in A2780. However, in our study, when examined
A2780 cell line, neither of the markers showed positive ex-
pression. Apart from CD44, many studies refer CD24 with
vital role in ovarian cancer metastasis, and it can be used
as a potential CSC marker [69, 89, 97, 98]. Recently, Gao
et al. [97] demonstrated that 5000 CD24+ cells could form
tumours in animal models with high expression of stemness
genes, while the same number of CD24− cells showed non-
tumourigenic eﬃciency. We found that 20% of CD44+
SKOV3 cells expressed CD24, while CAOV3 showed lower
expression of CD44 (40%) and higher expression of CD24
(80%) see Figure 1. Most OVCAR3 cells expressed CD24
with lack of CD44 expression (Figure 1). This indicated that
OVCAR3 is more of epithelial phenotype compared to other
cell lines. Nevertheless, unless these cells from each cell line
were isolated and studied through xenograft experiments,
their tumourigenic ability cannot be concluded.
In their study, Stuelten et al. [53] demonstrated CD44−
cells generated both CD44+ and CD44− phenotypes in
OVCAR5celllinereﬂectingitsstemcellproperties.Although
such consequence is contrasting with CD44+ cells in breast
cancer [28], eventually it has shown only CD44+ cells possess
greater clonogenic ability than CD44− cells. This may
strongly support the interconversion of CD44 phenotype
during tumourigenesis, indicating the diﬀerential expression
of markers in tumours. However, CD44 is expressed in
almost all cancers, likewise, recent reports show CD24 is
also enriched in ovarian CSCs. Wei et al. [69] demonstrated
that CD44+CD24+EpCAM+ phenotypes in human ovarian
cancer cell lines are enriched for stem/progenitor cells clono-
genic ability. Clearly, the notable marker combination is yet
to be conﬁrmed.
12.CD44/CD24 inProstateand
PancreaticCancers
The CSC research in prostate and pancreatic cancers remains
fresh. Only recently, some potential markers were eluci-
dated and found few populations comprising tumour-ini-
tiating ability. In pancreatic cancer, CD44+/CD24+ was de-
monstrated as potential phenotype to isolate CSCs [99].Clinical and Developmental Immunology 7
Later, CD44+/CD24+/ESA+ cells were referred to CSCs with
0.5%–1% of all pancreatic cancer cells [100]. However,
Qiang et al. [101] demonstrated CD44+/CD133− pheno-
type as a useful marker combination in predicting clinical
outcome. On the other hand, another study reported that
CD44+/CD133+ cells were enriched with tumour-initiating
characteristics [102]. In pancreatic cancer initially, Collins
et al. [103] found CD44+α2β+D133+ p o p u l a t i o nw a sa b l et o
diﬀerentiatetomixedphenotypeinprostatecancer.Lateron,
Patrawala et al. [104], using several prostate cell lines and
xenograft tumours, reported high expression of CD44+ cells,
and these cells enhanced proliferation in vitro and tumour
initiation and metastasis in vivo [105]. Subsequently, Hurt et
al. [106] isolated CD44+/CD24− cells from prostate cancer
and identiﬁed tumour-initiating ability in this phenotype
showing clonogenic and diﬀerentiation capability. It was
rather supported by other studies indicating CD44 role in
tumour invasion but with no clear information about meta-
stasis [53, 64, 107]. Thus, when compared to other cancers,
the knowledge about prostate CSCs seems to be inadequate
and requires further investigations to ﬁnd prominent com-
bination of surface markers [108]. These studies represent
CD44 as a potential marker, but it is too ambiguous with
its counterpart combination in both pancreatic and prostate
cancers. As CD24 and CD133 are enriched within epithelial
and diﬀerentiated cells [109], more elucidations may require
to deﬁne potential marker combination.
13. CD44/CD24 inColorectal, Lung, and
Renal Cancers
The ambiguity exists in these cancer types as well. In colorec-
tal cancer, Shmelkov et al. [110] reported the interconversion
ofCD133+toCD133− phenotypeaftermetastasisseemstobe
similarasinbreastcancer.Also,theydemonstratedthatthese
two populations could initiate tumours. RNA interference
(RNAi) studies of Du et al. [15] indicate that CD44 as a
potential marker for CSCs in colorectal cancer and cells with
high expression of CD44 along with CD133 in HCT116
showed tumour-initiating capability [60, 111]. These con-
clusions infer that CD44 in coexistence with CD133 may
have high tumourigenic activity rather than with CD24;
whereas later studies reported that CD133 was not expressed
in all solid tumours and may not be considered as a coun-
terpart of CD44. Instead, EpCAMhigh/CD44+/CD166+ was
suggested as robust CSC phenotype for isolation of CSCs
[13]. However, recent studies on colorectal cancer cell lines
[8] demonstrated that CD44+/CD24+ cells showed greater
clonogenic ability in vitro and tumour initiation in vivo.
This phenotype is diﬀerentiated to all four combinations of
CD44/CD24 cells. But one amongst cell lines is HCT116,
which is known to be a highly aggressive cell line with little
or no capacity to diﬀerentiate and known to possess high
proportion of stem cell markers [13]. HCT116 expresses
CD44+/CD24− phenotype cells with less clonogenic ability
[8]. This is similar to studies of Ahmed et al. [112] showing
very low levels of CD24 in HCT116. Our work on HCT166
(Figure 1) also showed high expression of CD44 with no
expressionofCD24.However,thesourceofCSCincolorectal
cancer is controversial and has to be elucidated completely
[14].
We analyzed COR L23, a nonsmall cell lung cancer cell
line that was completely negative for both CD44 and CD24
markers (Figure 1). No strong evidences showed CD44 and
CD24 analysis on COR L23. CD44 is believed to be a poten-
tial marker in lung cancer but not expressed in all lung can-
cer types. Therefore, it may not be considered as a bona
ﬁde CSC marker. Nonetheless, the CSCs in lung cancer are
still remaining to be explored which has not been studied
intensively as other cancers [26]. We also considered CAKI2,
whichisaprimaryclearcellrenalcarcinomacelllinetocom-
pare the CD44 and CD24 expression. We found that almost
all CAKI2 cells express CD44 and 55% of them express
CD24. Though studies indicate high expression of CD24 and
CD44 in renal cancer [113–115], more investigations with
diﬀerent experimental approaches are required to examine
their importance as CSCs.
14. Conclusion
The ambiguity of CSC markers is persisting despite of large
body of literature and information. Additional in-depth
knowledge to the present available information is necessary
toexploremechanismsinvolvedintumourdevelopmentand
maintenance. Further investigations are necessary to deter-
mine speciﬁc marker proﬁles to each tumour type and pat-
terns in each cell line since it appears to have high distinction
between cell lines amongst the same tumour types and dif-
ferent tumour types. CD44 appears to have a signiﬁcant reg-
ulatory role in almost all cancer types and more elucidations
on this marker may contribute to evaluate its prognostic
importance.TheregulatoryinteractionofCD44insignalling
pathways in tumour cells remains unresolved. CD24 being
an epithelial marker, it may not be expressed in all cancers
but seems to have a signiﬁcant role in those expressing
tumours. Close understanding of CSC origin and function
is necessary. As all tumours have diﬀerential phenotype, it
is obvious to express various speciﬁc markers in regard to
the tissue origin and functional properties. Studies also
indicate high variation amongst their proportions. Hence,
proﬁling the ultimate combination of markers based on
their physiological and functional properties in each tumour
could help in designating a speciﬁc marker combination to
each tumour subset. More intensive studies may help reduc-
ingtheambiguityamongstavailableinformationandﬁnding
potential prognostic CSC markers.
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